Compare WPRT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WPRT | ATRA |
|---|---|---|
| Founded | 1995 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.6M | 38.9M |
| IPO Year | 2006 | 2014 |
| Metric | WPRT | ATRA |
|---|---|---|
| Price | $1.98 | $8.86 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 2 | 2 |
| Target Price | $4.38 | ★ $5.00 |
| AVG Volume (30 Days) | 45.1K | ★ 3.0M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $28.74 | N/A |
| P/E Ratio | ★ N/A | $3.31 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.54 | $3.92 |
| 52 Week High | $4.14 | $19.15 |
| Indicator | WPRT | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 69.47 |
| Support Level | $1.80 | $4.35 |
| Resistance Level | $2.13 | $13.14 |
| Average True Range (ATR) | 0.11 | 0.90 |
| MACD | -0.01 | 0.49 |
| Stochastic Oscillator | 45.16 | 54.85 |
Westport Fuel Systems Inc is an organization engaged in the engineering, manufacturing, and supply of alternative fuel systems and components for transportation applications. It has three operating segments; the Original Equipment Manufacturers segment-design, manufacture, and sell alternative fuel systems, components and electronics, and related engineering services, to OEMs that serve light-duty, medium-duty, and heavy-duty customers, the Independent Aftermarket segment includes IAM products, conversion kits, and components allow for the conversion of vehicles after being sold to the end-user through a network of dealers and installers, and Corporate includes public company activities, corporate oversight, financing and capital allocation.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).